ColbertJD, StoneJA. Statin use and the risk of incident diabetes mellitus: A review of the literature. Can J Cardiol, 2012; 28:581–589.
2.
Cholesterol Treatment Trialists (CTT) Collaboration. BaigentC, Blackwellet al.Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376:1670–1681.
3.
MarrsJC. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: Focus on combination therapy with colesevelam HCl. Drugs Aging, 2012; 29:e1–e12.
4.
PreissD, SattarN. Pharmacotherapy: Statins and new-onset diabetes—the important questions. Nat Rev Cardiol, 2012; 9:190–192.
5.
RidkerPM, DanielsonE, FonsecaFAet al.JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359:2195–2207.
6.
FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm/. 2013 March 1.
7.
SattarN, PreissD, MurrayHMet al.Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010; 275:735–742.
8.
PreissD, SeshasaiSRK, WelshPet al.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA, 2011; 305:2556–2564.
9.
PreissD, SattarN. Statins and the risk of new-onset diabetes; a review of recent evidence. Curr Opin Lipidol, 2011; 22:460–466.
10.
JialalI, SmithG. Managing the dyslipidemia of metabolic syndrome: Beyond statin therapy. Metab Syndr Relat Disord, 2012; 10:159–160.
11.
MarxN. Commentary on ‘Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis' by Preiss et al. Diab Vasc Dis Res, 2012; 9:78.
12.
JialalI, DevarajS. Statin therapy for the metabolic syndrome: The evidence base. Metab Syndr Relat Disord, 2009; 7:393–396.
13.
DevarajS, RosensonRS, JialalI. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am, 2004; 33:431–453.
14.
The AIM-HIGH Investigator. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365:2255–2267.
15.
FlorentinM, LiberopoulosEN, RizosCVet al.Colesevelam plus rosuvastatin 5, mg/day versus rosuvastatin 10 mg/day alone on marker of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord, 2012e-pub ahead of print10.1089/met.2012.0103(PMID:23170931).
16.
VegaGL, DunnFL, GrundySM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol, 2011; 108:1129–1135.
17.
HandelsmanY, GoldbergRB, GarveyWTet al.Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: A randomized, prospective study. Endocr Pract, 2010; 16:617–628.
18.
BaigentC, LandrayMJ, ReithCet al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Production): A randomised placebo-controlled trial. Lancet, 2011; 377:2181–2192.
19.
FDA Advisory Committee Background Information: Ezetimibe/Simvastatin and Ezetimibe–SHARP Study Available at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM277652.pdf/. Accessed March 1, 2013.
20.
BaysHE, DavidsonMH, MassaadRet al.Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)Am J Cardiol, 2011; 108:523–530.
